The University of Chicago Header Logo

Connection

Peter Riedell to Humans

Back to Details
This is a "connection" page, showing publications Peter Riedell has written about Humans.
Peter Riedell
Connection Strength
0.747
Humans
  1. CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges. J Immunother Cancer. 2025 Jun 05; 13(6).
    View in: PubMed
    Score: 0.030
  2. Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis. Blood Adv. 2025 Mar 11; 9(5):1232-1241.
    View in: PubMed
    Score: 0.029
  3. Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. Blood Adv. 2024 10 22; 8(20):5346-5354.
    View in: PubMed
    Score: 0.029
  4. BsAbs before CD19 CAR-T: full speed ahead! Blood. 2024 07 18; 144(3):249-251.
    View in: PubMed
    Score: 0.028
  5. Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review. Target Oncol. 2024 07; 19(4):495-510.
    View in: PubMed
    Score: 0.028
  6. If They RECUR, You Should Refer: A Community Oncologist Patient ID Roundtable Summary. Transplant Cell Ther. 2024 01; 30(1):14-16.
    View in: PubMed
    Score: 0.027
  7. Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):83-93.
    View in: PubMed
    Score: 0.027
  8. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas. Transplant Cell Ther. 2022 10; 28(10):669-676.
    View in: PubMed
    Score: 0.024
  9. Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. Br J Haematol. 2021 12; 195(5):757-763.
    View in: PubMed
    Score: 0.023
  10. Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. Transplant Cell Ther. 2021 11; 27(11):911.e1-911.e7.
    View in: PubMed
    Score: 0.023
  11. Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. Leuk Lymphoma. 2021 06; 62(6):1497-1501.
    View in: PubMed
    Score: 0.022
  12. Advances in CAR T-Cell Therapy for Aggressive B-NHL. Clin Lymphoma Myeloma Leuk. 2020 09; 20 Suppl 1:S94-S97.
    View in: PubMed
    Score: 0.021
  13. Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma. Leuk Lymphoma. 2020 04; 61(4):799-807.
    View in: PubMed
    Score: 0.020
  14. Double hit and double expressors in lymphoma: Definition and treatment. Cancer. 2018 12 15; 124(24):4622-4632.
    View in: PubMed
    Score: 0.019
  15. Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL? Clin Lymphoma Myeloma Leuk. 2018 02; 18(2):91-97.
    View in: PubMed
    Score: 0.018
  16. Post-autologous transplant maintenance therapies in lymphoma: current state and future directions. Bone Marrow Transplant. 2018 01; 53(1):11-21.
    View in: PubMed
    Score: 0.018
  17. A drug safety evaluation of rituximab and risk of hepatitis B. Expert Opin Drug Saf. 2014 Jul; 13(7):977-87.
    View in: PubMed
    Score: 0.014
  18. New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma. Blood Adv. 2026 Jan 13; 10(1):217-227.
    View in: PubMed
    Score: 0.008
  19. A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL. Blood Adv. 2025 Nov 11; 9(21):5665-5675.
    View in: PubMed
    Score: 0.008
  20. Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis. Blood Adv. 2025 Nov 11; 9(21):5654-5662.
    View in: PubMed
    Score: 0.008
  21. Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study. Blood Adv. 2025 Aug 12; 9(15):3694-3705.
    View in: PubMed
    Score: 0.008
  22. Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis. Transplant Cell Ther. 2025 Dec; 31(12):1000.e1-1000.e11.
    View in: PubMed
    Score: 0.008
  23. Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma. Blood. 2025 Jun 05; 145(23):2762-2767.
    View in: PubMed
    Score: 0.007
  24. Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study. Blood. 2025 May 15; 145(20):2303-2311.
    View in: PubMed
    Score: 0.007
  25. Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma. Nat Commun. 2025 May 06; 16(1):4205.
    View in: PubMed
    Score: 0.007
  26. Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma. Transplant Cell Ther. 2025 Jul; 31(7):419-433.
    View in: PubMed
    Score: 0.007
  27. Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis. Blood Cancer J. 2025 Apr 15; 15(1):65.
    View in: PubMed
    Score: 0.007
  28. Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review. Target Oncol. 2025 Mar; 20(2):217-234.
    View in: PubMed
    Score: 0.007
  29. Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry. J Immunother Cancer. 2025 Feb 09; 13(2).
    View in: PubMed
    Score: 0.007
  30. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet. 2025 01 11; 405(10473):127-136.
    View in: PubMed
    Score: 0.007
  31. A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas. Clin Lymphoma Myeloma Leuk. 2025 May; 25(5):328-336.
    View in: PubMed
    Score: 0.007
  32. Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy. Blood Adv. 2024 07 23; 8(14):3785-3797.
    View in: PubMed
    Score: 0.007
  33. CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience. Blood Adv. 2024 07 09; 8(13):3528-3531.
    View in: PubMed
    Score: 0.007
  34. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas. Blood Adv. 2024 07 09; 8(13):3507-3518.
    View in: PubMed
    Score: 0.007
  35. Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission. Blood Cancer J. 2024 07 08; 14(1):108.
    View in: PubMed
    Score: 0.007
  36. Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis. Am J Hematol. 2024 08; 99(8):1624-1627.
    View in: PubMed
    Score: 0.007
  37. Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis. Leukemia. 2024 Jul; 38(7):1564-1569.
    View in: PubMed
    Score: 0.007
  38. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update. Blood. 2024 04 25; 143(17):1713-1725.
    View in: PubMed
    Score: 0.007
  39. Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity. Nature. 2023 11; 623(7989):1034-1043.
    View in: PubMed
    Score: 0.007
  40. Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma. Blood Adv. 2023 09 26; 7(18):5579-5585.
    View in: PubMed
    Score: 0.007
  41. Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. Blood Adv. 2023 09 12; 7(17):4765-4772.
    View in: PubMed
    Score: 0.007
  42. Infectious complications of car T-cell therapy: A longitudinal risk model. Transpl Infect Dis. 2023 Nov; 25 Suppl 1:e14148.
    View in: PubMed
    Score: 0.007
  43. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv. 2023 08 22; 7(16):4528-4538.
    View in: PubMed
    Score: 0.007
  44. Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood Adv. 2023 07 11; 7(13):3192-3198.
    View in: PubMed
    Score: 0.007
  45. A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma. Blood Adv. 2023 07 11; 7(13):2983-2993.
    View in: PubMed
    Score: 0.007
  46. Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results. Blood Adv. 2023 06 13; 7(11):2283-2286.
    View in: PubMed
    Score: 0.007
  47. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients. Eur Heart J. 2023 06 09; 44(22):2029-2042.
    View in: PubMed
    Score: 0.007
  48. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023 08 19; 402(10402):641-654.
    View in: PubMed
    Score: 0.007
  49. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med. 2023 07 13; 389(2):148-157.
    View in: PubMed
    Score: 0.006
  50. Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma. Transplant Cell Ther. 2023 07; 29(7):449.e1-449.e7.
    View in: PubMed
    Score: 0.006
  51. Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2023 03 28; 7(6):963-970.
    View in: PubMed
    Score: 0.006
  52. A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Adv. 2023 02 14; 7(3):285-292.
    View in: PubMed
    Score: 0.006
  53. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022 08; 23(8):1066-1077.
    View in: PubMed
    Score: 0.006
  54. Loss of 5-hydroxymethylcytosine expression is near-universal in B-cell lymphomas with variable mutations in epigenetic regulators. Haematologica. 2022 04 01; 107(4):966-969.
    View in: PubMed
    Score: 0.006
  55. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood. 2022 03 24; 139(12):1794-1806.
    View in: PubMed
    Score: 0.006
  56. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022 04; 28(4):735-742.
    View in: PubMed
    Score: 0.006
  57. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022 02; 28(2):325-332.
    View in: PubMed
    Score: 0.006
  58. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022 02 17; 386(7):640-654.
    View in: PubMed
    Score: 0.006
  59. Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. JAMA Oncol. 2021 Jul 01; 7(7):993-1003.
    View in: PubMed
    Score: 0.006
  60. Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021 06 17; 137(24):3454-3459.
    View in: PubMed
    Score: 0.006
  61. Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. J Geriatr Oncol. 2021 05; 12(4):585-591.
    View in: PubMed
    Score: 0.005
  62. Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. Biol Blood Marrow Transplant. 2020 07; 26(7):1239-1246.
    View in: PubMed
    Score: 0.005
  63. Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 05; 26(5):1025-1027.
    View in: PubMed
    Score: 0.005
  64. Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. Bone Marrow Transplant. 2020 06; 55(6):1161-1168.
    View in: PubMed
    Score: 0.005
  65. Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019 11 26; 3(22):3488-3498.
    View in: PubMed
    Score: 0.005
  66. Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. Haematologica. 2020 08; 105(8):e404-e407.
    View in: PubMed
    Score: 0.005
  67. Diagnostic Evaluation in Primary CNS Lymphoma. Neurologist. 2018 Mar; 23(2):53-54.
    View in: PubMed
    Score: 0.005
  68. Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. Am J Hematol. 2016 10; 91(10):1002-7.
    View in: PubMed
    Score: 0.004
  69. Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans. J Natl Cancer Inst. 2016 11; 108(11).
    View in: PubMed
    Score: 0.004
  70. Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma. Thromb Res. 2016 Jul; 143:86-90.
    View in: PubMed
    Score: 0.004
  71. Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. J Geriatr Oncol. 2015 May; 6(3):211-8.
    View in: PubMed
    Score: 0.004
  72. Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone. Br J Haematol. 2014 Dec; 167(5):699-702.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.